Stockreport

Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”

Coya Therapeutics, Inc.  (COYA) 
PDF Combination biologics with LD IL-2 as a backbone may represent next-generation approaches that target complex immune pathways in neurodegenerative diseasesExpansion of C [Read more]